Mark E. Anderson

Mark E. Anderson

Auto-generated profile, based on publicly available information

Mark E. Anderson

Department of Medicine, Johns Hopkins School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TRTyler P. Rasmussen
Tyler P. Rasmussen
YWYuejin Wu
Yuejin Wu
MJMei-Ling A. Joiner
Mei-Ling A. Joiner
OKOlha M. Koval
Olha M. Koval
NWNicholas R. Wilson
Nicholas R. Wilson
MAMark E. Anderson
Mark E. Anderson
Significance: Mitochondrial Ca 2+ is a fundamental signal that allows for adaptation to physiological stress but a liability during ischemia-reperfusion injury in heart. On one hand, mitochondrial Ca 2+ entry coordinates energy supply and demand in myocardium by increasing the activity of matrix dehydrogenases to augment ATP production by oxidative phosphorylation. On the other hand, inhibiting mitochondrial Ca 2+ overload is promulgated as a therapeutic approach to preserve myocardial tissue following ischemia-reperfusion injury. We developed a new mouse model of myocardial-targeted transgenic dominant-negative mitochondrial Ca 2+ uniporter (MCU) expression to test consequences of chronic loss of MCU-mediated Ca 2+ entry in heart. Here we show that MCU inhibition has unanticipated consequences on extramitochondrial pathways affecting oxygen utilization, cytoplasmic Ca 2+ homeostasis, physiologic responses to stress, and pathologic responses to ischemia-reperfusion injury.

17 February 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
PUPriya Umapathi
Priya Umapathi
OMOlurotimi O. Mesubi
Olurotimi O. Mesubi
PBPartha S. Banerjee
Partha S. Banerjee
NANeha Abrol
Neha Abrol
QWQinchuan Wang
Qinchuan Wang
MAMark E. Anderson
Mark E. Anderson
Background: Heart failure is a leading cause of death worldwide and is associated with the rising prevalence of obesity, hypertension, and diabetes. O -GlcNAcylation (the attachment of O -linked β-N-acetylglucosamine [ O -GlcNAc] moieties to cytoplasmic, nuclear, and mitochondrial proteins) is a posttranslational modification of intracellular proteins and serves as a metabolic rheostat for cellular stress. Total levels of O -GlcNAcylation are determined by nutrient and metabolic flux, in addition to the net activity of 2 enzymes: O -GlcNAc transferase (OGT) and O -GlcNAcase (OGA). Failing myocardium is marked by increased O -GlcNAcylation, but whether excessive O -GlcNAcylation contributes to cardiomyopathy and heart failure is unknown. Methods: We developed 2 new transgenic mouse models with myocardial overexpression of OGT and OGA to control O -GlcNAcylation independent of pathologic stress. Results: We found that OGT transgenic hearts showed increased O -GlcNAcylation and developed severe dilated cardiomyopathy, ventricular arrhythmias, and premature death. In contrast, OGA transgenic hearts had lower O -GlcNAcylation but identical cardiac function to wild-type littermate controls. OGA transgenic hearts were resistant to pathologic stress induced by pressure overload with attenuated myocardial O -GlcNAcylation levels after stress and decreased pathologic hypertrophy compared with wild-type controls. Interbreeding OGT with OGA transgenic mice rescued cardiomyopathy and premature death, despite persistent elevation of myocardial OGT. Transcriptomic and functional studies revealed disrupted mitochondrial energetics with impairment of complex I activity in hearts from OGT transgenic mice. Complex I activity was rescued by OGA transgenic interbreeding, suggesting an important role for mitochondrial complex I in O -GlcNAc–mediated cardiac pathology. Conclusions: Our data provide evidence that excessive O -GlcNAcylation causes cardiomyopathy, at least in part, attributable to defective energetics. Enhanced OGA activity is well tolerated and attenuation of O -GlcNAcylation is beneficial against pressure overload–induced pathologic remodeling and heart failure. These findings suggest that attenuation of excessive O -GlcNAcylation may represent a novel therapeutic approach for cardiomyopathy.

20 January 2023 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Open access
OGOscar E. Reyes Gaido
Oscar E. Reyes Gaido
LNLubika J. Nkashama
Lubika J. Nkashama
KSKate L. Schole
Kate L. Schole
QWQinchuan Wang
Qinchuan Wang
PUPriya Umapathi
Priya Umapathi
MAMark E. Anderson
Mark E. Anderson
CaMKII (the multifunctional Ca2+ and calmodulin-dependent protein kinase II) is a highly validated signal for promoting a variety of common diseases, particularly in the cardiovascular system. Despite substantial amounts of convincing preclinical data, CaMKII inhibitors have yet to emerge in clinical practice. Therapeutic inhibition is challenged by the diversity of CaMKII isoforms and splice variants and by physiological CaMKII activity that contributes to learning and memory. Thus, uncoupling the harmful and beneficial aspects of CaMKII will be paramount to developing effective therapies. In the last decade, several targeting strategies have emerged, including small molecules, peptides, and nucleotides, which hold promise in discriminating pathological from physiological CaMKII activity. Here we review the cellular and molecular biology of CaMKII, discuss its role in physiological and pathological signaling, and consider new findings and approaches for developing CaMKII therapeutics.

20 January 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYuejin Wu
Yuejin Wu
TRTyler P. Rasmussen
Tyler P. Rasmussen
OKOlha M Koval
Olha M Koval
MJMei-Ling A. Joiner
Mei-Ling A. Joiner
DHDuane D. Hall
Duane D. Hall
MAMark E. Anderson
Mark E. Anderson
Heart rate increases are a fundamental adaptation to physiological stress, while inappropriate heart rate increases are resistant to current therapies. However, the metabolic mechanisms driving heart rate acceleration in cardiac pacemaker cells remain incompletely understood. The mitochondrial calcium uniporter (MCU) facilitates calcium entry into the mitochondrial matrix to stimulate metabolism. We developed mice with myocardial MCU inhibition by transgenic expression of a dominant-negative (DN) MCU. Here, we show that DN-MCU mice had normal resting heart rates but were incapable of physiological fight or flight heart rate acceleration. We found that MCU function was essential for rapidly increasing mitochondrial calcium in pacemaker cells and that MCU-enhanced oxidative phoshorylation was required to accelerate reloading of an intracellular calcium compartment before each heartbeat. Our findings show that MCU is necessary for complete physiological heart rate acceleration and suggest that MCU inhibition could reduce inappropriate heart rate increases without affecting resting heart rate.

1 February 2017 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
NFNing Feng
Ning Feng
MAMark E. Anderson
Mark E. Anderson

1 December 2015 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
MAMark E. Anderson
Mark E. Anderson